Publicaciones en colaboración con investigadores/as de Yale University (14)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  3. MIF is a common genetic determinant of COVID-19 symptomatic infection and severity

    QJM : monthly journal of the Association of Physicians, Vol. 116, Núm. 3, pp. 205-212

2022

  1. A first update on mapping the human genetic architecture of COVID-19

    Nature

  2. Whole-genome sequencing reveals host factors underlying critical COVID-19

    Nature, Vol. 607, Núm. 7917, pp. 97-103

2021

  1. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

    Nature Genetics, Vol. 52, Núm. 1, pp. 56-73

2017

  1. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

    Nature Genetics, Vol. 49, Núm. 5, pp. 680-691

2015

  1. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

    JAMA - Journal of the American Medical Association, Vol. 313, Núm. 13, pp. 1347-1361

2008

  1. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma

    Clinical Endocrinology, Vol. 68, Núm. 4, pp. 618-634

2002

  1. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: A search for the early precursors of papillary cancer

    American Journal of Pathology, Vol. 160, Núm. 6, pp. 2157-2167

  2. RET activation and clinicopathologic features in poorly differentiated thyroid tumors

    Journal of Clinical Endocrinology and Metabolism, Vol. 87, Núm. 1, pp. 370-379

2001

  1. β-catenin dysregulation in thyroid neoplasms: Down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis

    American Journal of Pathology, Vol. 158, Núm. 3, pp. 987-996

1999

  1. Downregulation of p27(KIP1) and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories

    American Journal of Surgical Pathology, Vol. 23, Núm. 6, pp. 678-685